News

Open Text (OTEX) has been beaten down lately with too much selling pressure. While the stock has lost 13.7% over the past four weeks, there is light at the end of the tunnel as it is now in oversold

Shares of Welltower WELL have gained 19.3% over the past three months, outperforming the industry’s upside of 3.5%.

The rising healthcare spending and an aging population are likely to aid

U.S. stocks have held up impressively despite pockets of volatility, extending a strong upswing that began well over a year ago. Even with occasional pullbacks, major indexes remain quite close to

Sarepta Therapeutics SRPT announced that the FDA has approved significant changes to the label of Elevidys, its one-shot gene therapy for Duchenne muscular dystrophy (DMD). The revised labeling not

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts

Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.

The Zacks Premium

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm

Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.

The Zacks Premium

Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.

One of our most popular

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)

Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.

One of our most popular

Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.

The Zacks Premium

For the quarter ended September 2025, Aramark (ARMK) reported revenue of $5.05 billion, up 14.3% over the same period last year. EPS came in at $0.64, compared to $0.54 in the year-ago quarter.

The

• Shares of Spire Inc. (SR) declined 2.4% after the company reported a fourth-quarter fiscal 2025 loss of $0.47 per share, wider than the Zacks Consensus Estimate of a loss of $0.46 per share.
• CG

U.S. stocks ended mixed on Friday, with the Nasdaq ending higher after tech stocks tried to stage a rebound from the previous session’s losses, while investors worried that the Federal Reserve may

The Zacks Medical - Products industry is grappling with a difficult operating landscape marked by tariff-driven cost inflation, persistent supply-chain delays, and uneven macroeconomic conditions